Clinical Trial Detail

NCT ID NCT03147612
Title Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute lymphoblastic leukemia

Therapies

Pegfilgrastim

Blinatumomab

Vincristine Sulfate

Rituximab

Filgrastim

Ponatinib

Cyclophosphamide

Methotrexate

Cytarabine

Age Groups: adult senior

No variant requirements are available.